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In Absence of the Cellular Prion
Protein, Alterations in Copper
Metabolism and Copper-Dependent
Oxidase Activity Affect Iron
Distribution
Lisa Gasperini †, Elisa Meneghetti, Giuseppe Legname* and Federico Benetti *†
Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati, Trieste, Italy
Essential elements as copper and iron modulate a wide range of physiological functions.
Their metabolism is strictly regulated by cellular pathways, since dysregulation of metal
homeostasis is responsible for many detrimental effects. Neurodegenerative disorders
such as Alzheimer’s disease, Parkinson’s disease and prion diseases are characterized
by alterations of metal ions. These neurodegenerative maladies involve proteins that
bind metals and mediate their metabolism through not well-defined mechanisms. Prion
protein, for instance, interacts with divalent cations via multiple metal-binding sites and
it modulates several metal-dependent physiological functions, such as S-nitrosylation
of NMDA receptors. In this work we focused on the effect of prion protein absence
on copper and iron metabolism during development and adulthood. In particular, we
investigated copper and iron functional values in serum and several organs such as
liver, spleen, total brain and isolated hippocampus. Our results show that iron content is
diminished in prion protein-null mouse serum, while it accumulates in liver and spleen.
Our data suggest that these alterations can be due to impairments in copper-dependent
cerulopalsmin activity which is known to affect iron mobilization. In prion protein-null
mouse total brain and hippocampus, metal ion content shows a fluctuating trend,
suggesting the presence of homeostatic compensatory mechanisms. However, copper
and iron functional values are likely altered also in these two organs, as indicated
by the modulation of metal-binding protein expression levels. Altogether, these results
reveal that the absence of the cellular prion protein impairs copper metabolism and
copper-dependent oxidase activity, with ensuing alteration of iron mobilization from
cellular storage compartments.
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INTRODUCTION
Biometals are essential for a wide range of functions in living organisms. They are involved
in a variety of cellular pathways, from electrochemical gradient generation to enzyme
active site formation, DNA replication, oxygen transport, and oxidative/nitrosative stress
regulation. Metal absorption, metabolism, and excretion are tightly regulated processes. Although
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ion-specific transporters and metal-binding proteins exist,
absorption/excretion pathways are highly interconnected and
interdependent among different ionic species. In particular,
these interactions occur at two levels: (i) sharing of some
common transporters, e.g., divalent metal transporter 1;
(ii) existence of enzymes involved in the homeostasis of
several essential metals, for instance the copper-dependent
ferroxidase ceruloplasmin (Cp). Hence, the impairment of
metal homeostasis could affect the metabolism of a variety of
processes (Arredondo and Nunez, 2005; Kambe et al., 2008;
Bleackley and Macgillivray, 2011). Because of their chemistry,
transitionmetals, present in living organisms, need to be properly
compartmentalized and distributed to avoid detrimental effects,
such as reactive oxygen species (ROS)/reactive nitrogen species
(RNS) generation and abnormal metal-protein interaction.
Indeed, metal homeostasis dysregulation is highly damaging
and could result in developmental abnormalities and defects,
neurodegeneration or early death (Bush, 2000; Hellman and
Gitlin, 2002; Zecca et al., 2004; Gaier et al., 2013). Biometal
homeostasis alterations are closely related to neurodegenerative
mechanisms, mainly through two reactions: (i) aberrant metal–
protein association leading to protein aggregation and/or altered
enzyme activity; (ii) metal-catalyzed protein oxidation leading
to protein damage and denaturation (Bush, 2000). Several
disorders show a dysmetabolism of metal ions, such as Menkes’s
and Wilson’s disorders, aceruloplasminemia, Friedreich’s ataxia,
amyotrophic lateral sclerosis, schizophrenia, Alzheimer’s disease,
Parkinson’s disease, and prion diseases (Bush, 2000; Hellman
and Gitlin, 2002; Zecca et al., 2004; Gaier et al., 2013). Some of
these illnesses are due tomutations in well-definedmetal-binding
proteins, while Alzheimer’s disease, Parkinson’s disease and prion
diseases are protein aggregation disorders in which amyloid
precursor protein, α-synuclein and prion protein, respectively,
bind metals and are involved in metal metabolism with no
well-defined physiological functions.
Prion diseases are a class of neurodegenerative disorders
characterized by aggregation of an endogenous metal-binding
protein, the cellular prion protein (PrPC), which undergoes a
conformational change into a β-sheet enriched isoform, the
scrapie prion protein (PrPSc) (Prusiner, 2001). PrPC, encoded in
mouse by the Prnp gene, is a glycosylphosphatidylinositol (GPI)-
anchored protein widely expressed in the organism with the
highest level in the central nervous system (CNS), in particular
in the hippocampus (Horiuchi et al., 1995; Fournier et al.,
1998; Ning et al., 2005; Benvegnu et al., 2010). In the unfolded
N-terminal domain, PrPC contains the octapeptide region (OR)
which binds with high affinity copper, supporting its reduction
from Cu(II) to Cu(I), and with lower affinity manganese and zinc
(Brown et al., 1997; Jackson et al., 2001; Miura et al., 2005).
Results from PrPC-null (Prnp0/0) mice suggest a cellular role
for PrPC in which metals are crucial factors, such as their
involvement in antioxidant defense, neuroprotection against
excitotoxicity, myelin formation, and maintenance (Rangel et al.,
2007; Khosravani et al., 2008; Bremer et al., 2010). In particular,
we have recently shown that PrPC-copper complex modulates
NMDA receptor by S-nitrosylation (Gasperini et al., 2015).
Moreover, PrPC seems to be critical for metal homeostasis
(Brown, 2003; Singh et al., 2009c; Watt et al., 2012). Concerning
copper, PrPC has been proposed to pass it to transporters, and
also to buffer and redistribute it at synapses after its release during
synaptic transmission (Vassallo and Herms, 2003).
In this work, we focused our attention on the effect of PrPC
ablation on copper and ironmetabolism. Copper and iron are key
neurochemical factors whose aberrant interactions with target
proteins could induce reactions relevant for pathophysiology of
neurodegeneration. Copper is an essential metal for which PrPC
has the highest binding affinity (Lutsenko and Petris, 2003), and
iron is the most abundant trace element (Schroeder and Nason,
1971) whose metabolic pathways are highly dependent on copper
(Ganz, 2013). Since essential metals play key roles throughout
development and exert pleiotropic, metal-specific, and often cell-
specific effects on morphogenesis, growth, and differentiation,
we carried out our study by comparing Prnp+/+ and Prnp0/0
mice at different ages, from early post-natal days to 1-year-old.
In particular, we investigated copper and iron content, their
distribution and functional value as well as the genetic and
physiology of essential metal-binding proteins. Here, we show
that the absence of PrPC impairs copper metabolism and copper-
dependent oxidase activity, thus affecting iron mobilization.
EXPERIMENTAL PROCEDURES
Materials
Except where specified, all chemicals were obtained from
Sigma-Aldrich (St Louis, MO, USA). Protease inhibitor cocktail
was from Roche Diagnostics Corp. (Mannheim, Germany).
ECL detection reagent was from GE Healthcare (Waukesha,
WI, USA). Anti-Ctr1 ab123105, anti-Sod1 ab13499 were from
Abcam (Cambridge, UK). Recombinant anti-PrPC humanized
Fab D18 ABR-0D18 was purchased from InPro Biotechnology
(South San Francisco, CA, USA). Monoclonal anti-PrP SHA31
A03213 was from BertinPharma (Montigny le Bretonneux,
France). Anti-TfR1 13-6800 was from Invitrogen (Paisley, UK).
Anti-β-Tubulin III T2200, monoclonal anti-β-Actin Peroxidase
(AC-15) A3854, anti-Steap3 AV43515, anti-Atp7a AV33797,
anti-human Ferritin F5012 were from Sigma-Aldrich. Anti-Ccs
(FL-274) sc-20141, anti-FtH (H-53) sc-25617 were from Santa
Cruz Biotechnology (CA, USA). Anti-Cp 611488 was from BD
Transduction Laboratories (Milan, Italy). Anti-Tf GTX21223
was from GeneTex (Texas, USA). Anti-Fpn1 NBP1-21502
was from Novus Biologicals (Littleton, CO, USA). The anti-
Atp7b N-WNPD#1 was kindly provided by Prof. S. Lutsenko,
Johns Hopkins University, Baltimore, MD, USA. O-dianisidine
dihydrochloride D3252 was from Sigma-Aldrich. The ELISA kit
for Hepdicin SEB979Mu was from USCN (UK).
Animals
All experiments were performed in accordance with European
regulations [European Community Council Directive, November
24, 1986 (86/609/EEC)]. Experimental procedures were notified
to and approved by the Italian Ministry of Health, Directorate
General for Animal Health. All experiments were approved by
the local authority veterinary service of Trieste, Italy, and by the
Ethics Committee of the Scuola Internazionale Superiore di Studi
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Avanzati (SISSA), Trieste. All efforts were made to minimize
animal suffering and to reduce the number of animals used.
Inbred FVB/N (Friend virus B-type susceptibility-NIH) wild-
type and FVB Prnp0/0 mice were used in these experiments.
The FVB Prnp0/0 mice were obtained from George A. Carlson,
McLaughlin Research Institute, Great Falls, Montana, and were
bred by backcrossing with the original Prnp0/0 mice at least 20
times (Lledo et al., 1996).
Metal Ion Measurements
Metal ion content was measured in: serum, liver and spleen
collected from male mice at P15 (postnatal day 15), P30, P90,
P180, and P365; total brain and isolated hippocampus collected
from male mice at P1, P7, P30, P90, P180, P365. Liver and
spleen were extracted after animal perfusion with physiological
saline (0.9% NaCl) to minimize blood contamination, while
brains and hippocampi were extracted and dissected in bidistilled
water (ddH2O). To perform perfusion, animals were deeply
anesthetized with urethane (2.5 g/kg). To minimize variations,
all adult animals were perfused with the same saline volume,
while a lower volume was used for P15 mice. Samples were
completely dried in vacuum conditions and dissolved in 5
volumes of 65% nitric acid overnight at 70◦C, except P1
and P7 hippocampi which were dissolved in 10 volumes. To
prepare serum samples, the blood was collected by cardiac
puncture from deeply anestethized animals and centrifuged for
10min, RT at 900× g. To measure ceruloplasmin-bound copper,
serum samples were dialyzed against 50mM Tris-HCl, 20mM
EDTA, pH 7.5, using Slide-A-Lyzer MINI Dialysis Device, 7K
MWCO, 0.1mL (69560, Thermo Scientific, MA, USA) (Favier
and Ruffieux, 1988; Linder and Hazegh-Azam, 1996). An atomic
absorption spectrophotometer (AAnalyst 100, PerkinElmer, MA,
USA) was used to measure copper and iron in liver, spleen and
serum. Inductively coupled plasma mass spectroscopy (ICP-MS,
NexION 300D, PerkinElmer) was used to measure copper and
iron in total brains and isolated hippocampi.
Western Blot
Protein levels were measured in liver, serum, total brain, and
isolated hippocampus extracted from male mice at the same ages
at which metal content was determined. Liver and spleen were
extracted from saline-perfused animals to avoid blood protein
contamination. After extraction, the dissected structures were
immediately frozen in liquid nitrogen and stored at −80◦C.
Samples were homogenized and briefly sonicated in lysis buffer
(50 mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 0.5%
CHAPS, 10% glycerol, proteases inhibitors cocktail). Debris
were removed by centrifugation (10min, 2000× g, 4◦C) and
protein concentration was determined by BCA assay. For each
sample, the same protein amount (either 30 or 50µg, depending
on the protein) was separated on SDS–PAGE. On each gel,
four Prnp+/+, and four Prnp0/0 samples of the same age, but
deriving from different broods, were loaded, in order to compare
them. The acrylamide concentration was chosen depending on
the protein molecular weight. Proteins were transferred on
nitrocellulose and, after 1 h in blocking solution, membranes
were incubated overnight at 4◦C with the primary antibody,
except anti-β-Tubulin III, anti-β-Actin, anti-PrP, anti-Atp7b and
anti-Fp1, which were incubated 1 h at RT. After incubation with
the secondary antibody, membranes were developed with ECL
detection reagent and recorded by the digital imaging system
Alliance 4.7 (UVITEC, Cambridge, UK). Bands quantification
was performed with Uviband 15.0 software (UVITEC). Each
protein signal was normalized against either β-Actin or β-III
Tubulin, depending on the protein molecular weight, the signal
intensity and the secondary antibody. The normalized values
were compared between Prnp+/+ and four Prnp0/0 samples
by performing the Student’s T-test analysis, setting 2-tailed
distribution and unequal variance.
Antibodies
The following primary antibodies were used in TBST with 5%
milk: anti-Ctr1 1:500; anti-Sod1 1:1000; monoclonal anti-PrP
SHA31 1µg/ml; anti-PrP D18 1µg/ml; anti-TfR1 1:500; anti-β-
Tubulin III 1:5000; anti-β-Actin Peroxidase 1:10000; anti-Steap3
1:3000; anti-Atp7a 1:2000; anti-Ccs 1:400. The following primary
antibodies were used in TBST with 5% BSA: anti-Cp 1:250;
anti-Tf 1:2000; anti-human ferritin 1:1000; anti-FtH 1:200. The
anti-Fp1 was used 1:1000 in TBST with 3% BSA and 5% milk.
The anti-Atp7b N-WNPD#1 was incubated 1:4000 in PBST with
2% BSA, after blocking overnight at 4◦C in PBS with 3% BSA,
according to Prof. Lutsenko instruction.
Oxidase Activity
Oxidase activity was measured in different samples from
Prnp+/+ to Prnp0/0. Spleen and liver were extracted from
saline-perfused male mice (see Metal Ions Measurements) and
homogenized in PBS with 1.5% Triton X-100 and protease
inhibitors (Chen et al., 2004): entire spleen samples were
homogenized in 1.5 mL, while a liver piece was weighted and
homogenized in 6 volumes of buffer. Serum samples were
collected as described inMetal Ion Measurements paragraph. All
samples were either immediately processed for the enzymatic
assay or stored at 4◦C for 1–2 days. For each analyzed age,
samples were collected from Prnp+/+ to Prnp0/0 mice at the same
time to avoid biases due to different storage and ensuing different
loss of enzymatic activity. Serum Cp activity was measured
following the protocol published by Schosinsky (Schosinsky et al.,
1974). Briefly, 50µL serum (50µL ddH2O for the blank) were
added to 750µL acetate buffer (100mM sodium acetate, pH 5)
and heated for 5 min at 30◦C. O-dianisidine dihydrochloride was
dissolved 7.88mM in ddH2O, protected from the light, heated
at 30◦C for 5min and added to the samples (200µL per tube).
The reaction was run for 2.5 h and stopped adding 2mL of
9M sulfuric acid, then the absorbance (Abs) peak at 540 nm
was recorded. For spleen and liver, 100µL of homogenate were
added to 700µL acetate buffer. After adding 200µL substrate,
the reaction was carried out for 6 h (necessary to get a detectable
signal form tissues) and stopped with 2mL 9M sulfuric acid
to obtain a clearly detectable peak. The enzymatic activity was
expressed in International Units, in terms of substrate consumed:
Concentration of substrate oxidized = (Abs × 3 × V)/(9.6
× T) µmol/mL per minute, where: 9.6 is the molar extinction
coefficient of chromophore (ml µmol−1 cm−1); 3 = dilution
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factor for the final measured solution volume, taking into account
the addition of 2 mL sulfuric acid to 1 mL of reaction; V =
correction for sample volume used (50 µL for serum and 100 µL
for spleen and liver in 1 mL final volume); T is the incubation
time (min; Schosinsky et al., 1974).
To confirm the Cp contribution when measuring oxidase
activity, different conditions were used. Before adding
O-dianisidine, serum was pre-incubated at 30◦C for 5 min
with either 10 µM EDTA or 28mM sodium azide or 200µM
cuprizone (Levine and Peisach, 1963; Curzon, 1966; Benetti et al.,
2010), or pre-heated at 85◦C for 5min (Schosinsky et al., 1974).
Afterwards, reactions and enzymatic activity were performed
and calculated as described.
Hepdicin Determination in Serum
Serum samples were collected as described in Metal Ion
Measurements paragraph and stored at −80◦C upon addition
of proteases inhibitors cocktail. Samples were obtained from
P15, P30, P90, P180, and P300 male Prnp+/+ and Prnp0/0 mice.
Hepdicin levels were determined by using the ELISA kit for
Hepdicin SEB979Mu following the manifacturer’s instructions
Statistics
All the experiments were carried out by using, at least, four
biological replicates (i.e., 4 Prnp+/+ samples and 4 Prnp0/0).
The obtained data were statistically analyzed by performing
the Student’s T-test, setting parameters corresponding to the
unequal sample variants and two-tailed distribution. P < 0.05
were considered statistically significant.
RESULTS
PrPC-Null Mouse Serum Contains Lower
Levels of Copper Bound to Cp, Oxidase
Activity and Iron
To study the role of PrPC in metal metabolism, we first measured
copper and iron content in wild-type and PrPC-null mouse blood
serum. We performed this analysis at different ages, from P15 to
1-year-old, and expressed results as the ratio between Prnp0/0 and
Prnp+/+ ion concentration values. Results expressed in µg/mL
are reported in Figures S1A–C. We found that the total amount
of serum copper is not affected by PrPC absence, as shown in
Figure 1A. In physiological conditions, most of serum copper
(∼95%) is bound and transported by Cp (Harris and Gitlin,
1996). The remaining fraction is bound to macroglobulins and
albumin, and represents the so-called copper exchangeable pool
(Favier and Ruffieux, 1988; Linder and Hazegh-Azam, 1996). By
dyalizing serum against the divalent cation chelator EDTA, we
determined copper bound to Cp. Indeed, EDTA affinity constant
for copper is enough for chelating free and exchangeable copper
ions in serum (e.g., copper ions bound to albumin or small
molecules) but it is unable to complex Cp-bound copper (Favier
and Ruffieux, 1988). At all ages, Cp-bound copper is significantly
decreased in PrPC-null mouse serum compared to wild-type
animals (Figure 1A), suggesting a larger copper exchangeable
pool fraction in PrPC-null mice. The reduced amount of Cp-
bound copper in PrPC-null mouse serum seems not due to
differences in Cp expression level, as shown in Figure 1B, and
suggests an impairment in Cp ferroxidase activity. Measuring
serum Cp activity, we confirmed that it is lessened in Prnp0/0
mice compared to wild-type (Figure 1C). To verify the reduced
Cp activity in PrPC-null mice, Cp activity was determined in the
presence of EDTA as divalent cations chelator (e.g., iron, copper),
cuprizone as selective copper chelator unable to sequester copper
in the ceruloplasmin catalytic site, azide as specific inhibitor of
type 3 copper center responsible for ceruloplasmin activity, and
by heating samples for denaturating ceruloplasmin so preventing
its activity (Figure S2). While a slightly reduction in oxidase
activity of both wild type and PrP-null mice in the presence
of EDTA was observed, oxidase activity was strongly inhibited
by adding the specific inhibitor azide and by heating serum,
confirming the role of Cp in mediating oxidase activity. No
alterations in oxidase activity were observed adding CZ. Since
Cp ferroxidase activity mediates Fe2+ oxidation to Fe3+ for
incorportation into transferrin (Tf), which is the main iron
transporter, and iron mobilization from tissues (Osaki et al.,
1966, 1971), we measured iron content in PrPC-null and wild-
type mouse sera. Starting from P90, serum iron concentration
was reduced in Prnp0/0 mice compared to wild-type (Figure 1A).
However, no differences in serum Tf levels were observed
(Figure 1B).
In PrPC-null mouse serum, the lower level of copper-loaded
Cp (holoCp) results in lower oxidase activity, reduced iron export
from tissues and ensuing serum iron content. Being the total
amount of copper and Cp not altered, the mechanism of copper
loading into Cp is most likely the impaired pathway in Prnp0/0
mice.
Beside copper loading into Cp, another pathway altered in
Prnp0/0 mice is the iron uptake and/or transport from the
duodenum to the blood stream (Singh et al., 2009b), and
together the alterations likely cause serum iron deficiency. These
observations indicate that PrPC determines both Cp functionality
and iron uptake/transport from duodenum.
PrPC-Null Mouse Liver Shows Evidence of
Iron Accumulation and Deficit in Oxidase
Activity, Leading to Hepcidin Production
Incorporation of copper into Cp mainly occurs in the liver
(Terada et al., 1995). Therefore, we measured copper content in
Prnp0/0 and Prnp+/+ mouse liver during early development and
adulthood, and expressed results as the ratio between Prnp0/0 and
Prnp+/+ ion concentration values (Figure 2A). Results expressed
in µg/mL are reported in Figures S1D,E. Similarly to serum,
total copper content is not overall altered in Prnp0/0 mouse
liver, though a decrease of about 30% occurs at the early stage
P15 (Figure 2A). Our data show iron accumulation in the liver
starting from P90 (Figure 2A), corresponding to the reduction of
serum iron concentration (Figure 1A). As for serum Cp activity,
liver oxidase activity is diminished in Prnp0/0 mice (Figure 2B).
The activity of ferroxidases is necessary for iron eﬄux from stores
via Ferroportin1 (Fpn1). Indeed, in absence of ceruloplasmin
activity, iron accumulates in the liver causing anemia (Osaki
et al., 1971; Harris et al., 1999; Kosman, 2010; Ganz, 2013).
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FIGURE 1 | Comparison of Cu, Cp-bound Cu, Fe, Cp and Tf expression, Cp activity, and Hepcidin levels in wild-type and PrPC-null mouse serum at
different ages. (A) The graph shows the ratio of Cu, Cp-bound Cu, and Fe levels in Prnp0/0 and Prnp+/+ serum samples (P15, P30, P180 N = 5; P90 N = 6; P365
N = 4). (B) Representative Western blot images showing Cp and Tf levels in Prnp0/0 and Prnp+/+ serum samples are shown. The equal protein loading is also
shown by the ponceau staining. N = 4. (C) The graph shows the levels of Cp activity as U/mL in Prnp0/0 and Prnp+/+ serum (P15, P30, P180 N = 4; P90, P365
N = 3). (D) The graph shows the ratio of Hepcidin levels in Prnp0/0 and Prnp+/+ serum samples (N = 4). All error bars indicate SD; *p < 0.05; **p < 0.01.
Therefore, the decreased oxidase activity we observed in Prnp0/0
mouse liver and serum is likely the cause of iron accumulation in
the liver and decrease in the serum.
Since contrasting data on PrPC expression in mouse liver are
reported in literature (Miele et al., 2003; Peralta and Eyestone,
2009; Peralta et al., 2012; Arora et al., 2015), and considering
that 50 µg of liver protein extract were not enough to detect a
clear PrPC signal (data not shown), we verified PrPC expression
by performing immunoprecipitation from Prnp+/+ mouse liver,
with Prnp0/0 as negative control. The result confirmed the
expression of PrPC in this organ (Figure S3).
Serum iron homeostasis is regulated by a small peptide
hormone, hepcidin, produced by hepatocytes (Ganz, 2013).
Hepcidin binds divalent metal transporter 1 and Fpn1 and
induces their endocytosis and degradation. In this way, it
prevents iron absorption from enterocytes, and iron release from
iron stores and (mainly splenic) macrophages recycling senescent
erythrocytes. Hepcidin synthesis is regulated by iron levels in
intracellular stores and blood (Aoki et al., 2005; Detivaud et al.,
2005; Gehrke et al., 2005; Ramos et al., 2011; Feng et al., 2012).
Upon iron accumulation hepcidin expression is induced, while it
is reduced when hepatocyte and/or blood iron content decreases.
Measuring Prnp0/0 and Prnp+/+ mouse serum hepcidin levels,
we found higher hepcidin content in PrPC-null mice from P30 to
P180, lowering at P300 compared to wild-type mice (Figure 1D).
Higher hepcidin levels in adult Prnp0/0 mice is in agreement with
liver oxidase activity impairment and iron overload. In 1-year-
old Prnp0/0 mice, hepcidin is decreased and hepatic iron content
reduced. Hepcidin reduction is likely due to the prolonged serum
iron deficiency (Pigeon et al., 2001; Nicolas et al., 2002).
Focusing on copper and iron metabolic pathways in the liver,
we found that Cp and copper-transporting ATPase 2 (Atp7b)
expression levels are lower in Prnp0/0 mice compared to wild-
type animals (Figures 2C,D). These data, combined with lower
serum holoCp level and activity, suggest the formation of apoCp
and its intracellular degradation within hepatocytes (Hellman
and Gitlin, 2002). To exclude alterations at trascriptional level,
we compared Prnp0/0 and Prnp+/+ mice GPI anchored Cp
mRNA levels by qRT-PCR. No differences in Cp transcription
were observed (Figure S4A), suggesting that Cp decrease is
caused by a higher degradation rate. These findings support
the reduced Atp7b levels in PrP-null mice. Indeed, Atp7b is
devoted both to excrete copper into the bile and translocate it to
the trans-Golgi network (TGN) for its incorporation in copper-
binding proteins such as Cp (Gupta and Lutsenko, 2009). Lower
Atp7b expression levels in Prnp0/0 mice may result in failure of
copper incorporation into Cp, production of apo-Cp, and rapid
degradation.
Iron metabolic pathway is modulated by intracellular
iron content via iron-responsive proteins and iron-responsive
elements interaction. Intracellular iron accumulation reduces
iron uptake molecular mechanisms, like transferrin receptor 1
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FIGURE 2 | Comparison of Cu, Fe, oxidase activity, metal-binding protein expression levels in wild-type and PrPC-null mouse liver at different ages.
(A) The graph shows the ratio of Cu and Fe levels in Prnp0/0 and Prnp+/+ liver samples (P15, P90 N = 5; P30, P180, P365 N = 4). (B) The graph shows the levels of
oxidase activity as U/mL in Prnp0/0 and Prnp+/+ liver (P15, P90, P180, P365 N = 4; P30 N = 5). (C) Representative Western blot images showing metal-binding
protein levels in Prnp0/0 and Prnp+/+ liver samples. The constant level of the housekeeping protein (β-Actin) are also reported. (D) The graph shows the up- or
down-regulation of protein expression in Prnp0/0 samples compared to Prnp+/+, i.e., (Prnp0/0 protein OD/housekeeping OD)/(Prnp+/+ protein OD/housekeeping
OD), N = 4. All error bars indicate SD; *p < 0.05; **p < 0.01.
(TfR1), increasing iron export and storage mechanisms such as
Fpn1, ferritin H (FtH) and ferritin L (FtL) (Zecca et al., 2004;
Anderson et al., 2007). In Prnp0/0 liver, the expression level
of iron importer TfR1 is reduced, while iron exporter Fpn1
follows iron accumulation trend reaching the highest expression
level at ages P90-P180, the period with the highest iron content
(Figures 2C,D). Tf level is also increased in PrPC-null liver
compared to wild-type liver. Similarly to the other iron-binding
proteins, storage proteins FtH and FtL are differently expressed in
Prnp0/0 liver. In particular, FtH was less expressed at P15, when
also iron is slightly lower (though not statistically significant).
Then, FtH starts being overexpressed in agreement with iron
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accumulation. FtL tightly follows iron levels since it is not
expressed in P15 liver, is downregulated at P30, but overexpressed
in aged mice in agreement with iron overload (Figures 2C,D). In
1-year-old PrP-null liver, its expression decreases in agreement
with iron content reduction. The different modulation of FtH
and FtL expression in Prnp0/0 liver can be related to a different
regulation at post-transcriptional level. Indeed, FtH and FtL
independently respond to iron levels, and FtL is more tightly
regulated by iron at a post-transcriptional level than FtH
(Sammarco et al., 2008; Arosio et al., 2009).
Iron accumulation is not due to changes in six-
transmembrane epithelial antigen of prostate 3 (Steap3).
This protein is highly expressed in the liver and acts as
metalloreductase in iron and copper uptake (Gomes et al., 2012).
Conversely from Cp, the expression level of Steap3 is not altered
in the liver of Prnp0/0 mice (Figure S4B).
Overall, these data suggest that PrPC absence does not alter
the global copper content but impairs the pathway of copper
loading into Cp. Consequently, Cp activity is compromised, and
iron is accumulated in the liver and not delivered to serum.
Although we observe the same modulation in Tf expression, our
data concerning liver iron content and Ferritin expression are
not in agreement with what previously published by Singh and
colleagues (Singh et al., 2009b), i.e., lower iron, FtH and FtL
levels in PrPC-null liver. Despite these discrepancies, our data
confirm iron dyshomeostasis in PrPC-null mice and support the
diminished oxidase activity in both liver and serum of Prnp0/0
mice as the cause of serum iron deficiency.
PrPC-Null Mouse Spleen Shows Decreased
Copper Content and Iron Accumulation
Which Causes Splenomegaly
Taking into account the alterations observed in the liver of
Prnp0/0 mice for iron and coppermetabolism, we investigated the
effects of PrPC absence on spleen, another fundamental organ for
metal ion homeostasis. First, we confirmed the presence of PrPC
in the spleen (Figure S3). Then, we measured copper and iron
content in wild-type and PrPC-null mouse spleen at the different
ages, and expressed results as the ratio between Prnp0/0 and
Prnp+/+ ion concentration values (Figure 3A). Results expressed
in µg/mL are reported in Figures S1F,G. Conversely from the
liver, we detected a strong reduction in copper content and
an increase in iron level starting from P30 in Prnp0/0 spleen
(Figure 3A). The copper content reduction is likely related to
alterations in its uptake due to PrPC ablation and lower Steap3
expression detected in PrPC-null spleen (Figures 3C,D). Steap3
is indeed involved in reducing Cu2+ to Cu+ for subsequent
internalization via Ctr1. Reduced Steap3 level suggests an
impairment of copper uptake leading to copper deficiency in
PrPC-null mouse spleen. Expression levels of the copper-binding
proteins Cp and Atp7b revealed no differences between Prnp+/+
and Prnp0/0 mouse spleen (Figure S5A), suggesting the correct
incorporation of copper into Cp. Indeed, oxidase activity in
spleen is not altered in PrPC-null mice, as shown in Figure S5B.
Similarly to the liver, iron metabolic pathway is altered
in Prnp0/0 mouse spleen earlier than iron accumulation
(Figures 3C,D), with the upregulation of Tf and TfR1. The
subsequent iron accumulation, occurring at P30 and P90 in
Prnp0/0 splenocytes, leads to downregulation of TfR1 and Tf, and
upregulation of FtH. At these ages, Fpn1 level is not affected
by PrPC absence, probably due to increased serum hepcidin
responsible for its degradation. In adult PrPC-null mice TfR1 and
Tf levels are upregulated, while Fpn1 expression level is reduced.
Therefore, we can hypothesize that spleen iron overload can be
linked to the drop in serum Cp activity, which is necessary for
iron eﬄux from Fpn1, and to the expression levels of Tf, TfR1
and Fpn1. These changes lead to splenomegaly, an enlargement
of the spleen caused by iron overload (Figure 3B). Splenomegaly
is commonly related to anemia and copper deficiency (Guo
et al., 2013; Shawki et al., 2015), as described by our results for
PrPC-null mice in previous paragraphs.
The atypical response to iron overload is related to
concomitant copper reduction in PrPC-null spleen. Indeed,
iron and copper homeostasis share common proteins and their
regulation is closely interconnected. For instance, the unexpected
TfR1 overexpression in presence of iron accumulation is due to
copper deficiency, as previously reported for copper deficient rats
(Auclair et al., 2006; Andersen et al., 2007). The iron overload we
observe in Prnp0/0 spleen is in contrast with findings previously
published (Singh et al., 2009b), but spleen iron accumulation
is consistent with our data showing serum iron deficiency and
splenomegaly.
PrPC-Null Mouse CNS Balances Copper
and Iron Homeostasis Dysregulation by
Modulating Transporters Expression
Since CNS is the organ with the highest PrPC expression
(Figure S3) and primary target of prion disorders, we analyzed
the impact of PrPC absence on copper and iron metabolism.
We analyzed the total brain and the isolated hippocampus. The
latter is the region showing PrPC expression at synapse and the
most prominent alterations in Prnp0/0 mouse model. We first
measured copper and iron content in wild-type and PrPC-null
mouse total brain and isolated hippocampus at different ages,
from P1 to 1-year-old, and expressed results as the ratio between
Prnp0/0 and Prnp+/+ ion concentration values (Figures 4A, 5A).
Results expressed in µg/mL are reported in Figures S1H–K. Both
copper and iron show a fluctuating behavior along ages in both
total brain and hippocampus, with a reduction in their content at
early stages (P1 and P7) and adulthood (P180), and an increase at
P30-P90 (Figures 4A, 5A).
By analyzing the expression pattern of copper and iron
metabolism proteins, we found some modulations in Prnp0/0
mouse total brain and isolated hippocampus which, at the same
time, can suggest a response to metal ion altered metabolism.
Copper chaperone for Sod1 (Ccs) is the only copper-binding
protein altered in total brain of PrPC-null mice (Figures 4B,C),
while no differences were found for Ctr1, Atp7a, Atp7b, Steap3,
Cp, and Sod1 (Figure S6). Iron metabolic pathway is highly
affected in Prnp0/0 mouse total brain, as indicated by the higher
levels of Tf and TfR1 and reduced expression of Fpn1 at all
the considered ages (Figures 4B,C). FtH is downregulated in
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FIGURE 3 | Comparison of Cu, Fe, and metal-binding protein expression levels in wild-type and PrPC-null mouse spleen at different ages. (A) The
graph shows the ratio of Cu and Fe levels in Prnp0/0 and Prnp+/+ spleen samples (P15 N = 3; P30 N = 4; P90, P180 N = 6; P365 N = 5). (B) The graph shows the
weight of spleen extracted from Prnp0/0 and Prnp+/+ mice; N = 4. (C) Representative Western blot images showing metal-binding protein levels in Prnp0/0 and
Prnp+/+ spleen samples. The constant level of the housekeeping protein (β-Actin) are also reported. (D) The graph shows the up- or down-regulation of protein
expression in Prnp0/0 samples compared to Prnp+/+, i.e., (Prnp0/0 protein OD/housekeeping OD)/ (Prnp+/+ protein OD/housekeeping OD); N = 4. All error bars
indicate SD; *p < 0.05; **p < 0.01; ***p < 0.001.
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FIGURE 4 | Analysis of Cu and Fe content and metal-binding protein expression in wild-type and PrPC-null mouse total brain at different ages. (A) The
graph shows the ratio of Cu and Fe levels in Prnp0/0 and Prnp+/+ brain samples (P1, P365 N = 4; P7, P30, P180 N = 6; P90 N = 5). (B) Representative Western
blot images showing metal-binding protein levels in Prnp0/0 and Prnp+/+ brain samples (N = 4). The constant level of the housekeeping proteins (β-III Tubulin and
β-Actin) are also reported. (C) The graph shows the up- or down-regulation of protein expression in Prnp0/0 samples compared to Prnp+/+, i.e., (Prnp0/0 protein
OD/housekeeping OD)/(Prnp+/+ protein OD/housekeeping OD). All error bars indicate SD; N = 4 minimum; *p < 0.05; **p < 0.01; ***p < 0.001.
juvenile Prnp0/0 mice and strongly upregulated in the adulthood
(Figures 4B,C), while no alterations in FtL level are found. The
differential expression of Tf, TfR1 and Fpn1, as well as the FtH
downregulation, correlates with iron deficiency phenotpe (Zecca
et al., 2004).
In Prnp0/0 mouse hippocampus, proteins involved in both
copper and iron metabolism are altered. The copper-binding
protein Ctr1 and Atp7a are upregulated at all stages, while
Cp and the intracellular chaperone Ccs are downregulated
(Figures 5B,C). Ctr1 upregulation suggests a compensatory
mechanism for copper uptake in the absence of PrPC. No changes
are observed for Steap3, Atp7b, and Sod1 (Figure S7). Although
Sod1 expression level is not affected by PrPC absence, the
downregulation of Ccs occurring in PrPC knockout CNS
may affect copper loading onto Sod1 (Culotta et al., 1997),
leading to the formation of the apo-Sod1 form. Therefore, Ccs
reduction may contribute to the diminished Sod1 antioxidant
activity registered in PrPC-null mice (Brown and Besinger,
1998; Kralovicova et al., 2009). Concerning iron metabolism,
TfR1 and Tf are increased along all ages, while the expression
level of the iron-storage proteins FtH and FtL is decreased
(Figures 5B,C). As observed in total brain, the altered expression
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FIGURE 5 | Analysis of Cu and Fe content and metal-binding protein expression in wild-type and PrPC-null mouse isolated hippocampus at different
ages. (A) The graph shows the ratio of Cu and Fe levels in Prnp0/0 and Prnp+/+ hippocampus samples (P1, P180, P365 N = 4; P7 N = 7; P30 N = 6; P90 N = 5).
(B) Representative Western blot images showing metal-binding protein levels in Prnp0/0 and Prnp+/+ hippocampal samples (N = 4). The constant level of the
housekeeping proteins (β-III Tubulin and β-Actin) are also reported. (C) The graph shows the up- or down-regulation of protein expression in Prnp0/0 samples
compared to Prnp+/+, i.e., (Prnp0/0 protein OD/housekeeping OD)/(Prnp+/+ protein OD/housekeeping OD). All error bars indicate SD; N = 4 minimum); *p < 0.05;
**p < 0.01; ***p < 0.001.
of iron-binding proteins correlates with iron deficiency status
(Zecca et al., 2004).
The presented results indicate that in the CNS of PrPC-null
mice, the expression of copper- (Cp, Ctr1, Ccs1) and iron-
binding proteins (Tf, TfR1, FtH, FtL, Fpn1) is regulated in line
with a copper and iron deficiency status. These findings are in
agreement with data previously reported (Singh et al., 2009b).
The fluctuating alterations of both copper and iron content may
result from the compensation induced by metal-binding protein
expression modulation.
CONCLUSIONS
Metal homeostasis is crucial to preserve physiological functions
in living organisms, and alterations in their absorption,
metabolism, and excretion have pathological implications.
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FIGURE 6 | Proposed model for PrPC role in copper and iron homeostasis. Wild-type PrPC mouse. In both liver and spleen, PrPC may bind Cu2+ released
from the blood Cu2+ exchangeable pool, reduce to Cu+ and pass it to Ctr1 for its uptake, or may function itself as a transporter by internalization. Therefore, in the
liver, PrPC may be involved in the transport of copper to the TGN where Atp7b load it on Cp. Hence, holo-Cp can be released in the serum or GPI-anchored on
(Continued)
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FIGURE 6 | Continued
hepatocytes, thus mediating iron export through its copper-dependent ferroxidase activity. PrPC-null mice. In the absence of PrPC, liver copper uptake is affected,
hence the formation of holo-Cp is diminished. Consequently, iron is accumulated in the liver, TfR1 level is decreased, while FtH and FtL levels are increased. Therefore,
hepcidin secretion is enhanced, with ensuing block of Fpn1. In the spleen, the absence of PrPC induces a reduction in copper uptake that, together with
hepcidin-mediated Fpn1 block, triggers iron accumulation, that, in turn, leads to splenomegaly. Liver and spleen iron accumulation results in decreased serum iron
content.Wild-type PrPC CNS. PrPC may bind Cu2+ released from the blood Cu2+ exchangeable pool and reduce to Cu+, and pass it to Ctr1 for its uptake, or may
function itself as a transporter by internalization. Therefore, PrPC may be involved in the intracellular transport of copper, and loading on Ccs. PrPC-null mouse CNS.
In PrPC-null blood, iron and Cp-bound copper levels are decreased. Therefore, compensatory mechanism maintain physiological copper and iron levels. In both total
brain and isolated hippocampus, Tf, TfR1, FtH, FtL are modulated in response to iron deficiency. Copper-binding protein Ctr1, Atp7a and Cp are modulated in the
hippocampus, responding to copper deficiency. Ccs is decreased in PrPC-null CNS, likely causing the decrease in Sod1 activity (Brown and Besinger, 1998;
Kralovicova et al., 2009). All the alterations observed in PrPC-null mouse have been reported as big arrows pointing up in case of increase, pointing down in case of
decrease. In the CNS scheme, *flanking the arrow indicates an alteration observed only in the isolated hippocampus, but not in the total brain.
Neurodegenerative disorders are characterized by impairment of
metal homeostasis, though the engaged molecular mechanisms
are not well-understood. Through its multiple metal-
binding sites, PrPC interacts with metals and modulates
their physiological functions, such as the S-nitrosylation of
NMDA receptors (Gasperini et al., 2015). On the other hand, it
has been shown that metals promote PrP aggregation (Jobling
et al., 2001; Younan et al., 2011; Migliorini et al., 2014). The
dual effect of metals on PrP depends on differences in their
functional value. To understand the impact of PrPC on metal
homeostasis and their functional value, we investigated changes
in copper and iron metabolism occurring in PrPC-null mice. The
Prnp gene knockout mimicks PrPC loss-of-function occurring
in prion diseases. Therefore, our results could also extend our
understanding of the molecular mechanisms underlying these
pathologies.
The results we obtained led us to hypothesize the model
described in Figure 6. PrPC absence causes a serum anemia with
a subsequent accumulation in the liver and spleen. No differences
in total copper content were observed in the serum and in the
liver, but oxidase activity of the copper-dependent Cp was lower
in PrPC-null mice compared to wild-type. The reduction in Cp
activity is likely due to altered incorporation of copper into Cp
with the subsequent formation of apo-Cp which is more prone
to degradation (Hellman and Gitlin, 2002). The diminished
oxidase activity affects Fe2+ to Fe3+ oxidation, thus impairing
iron release from stores and its incorporation into Tf. The atypical
behavior of iron and iron-binding proteins in the spleen may
be due to the concurrent copper reduction in PrPC-null spleen
(Auclair et al., 2006; Andersen et al., 2007).
Conversely from liver and spleen, copper and iron content in
PrPC-null mouse CNS presents fluctuating concentrations
implying the presence of homeostatic compensatory
mechanisms. The brain has the highest metabolic rate of
all organs and depends on oxidative metabolism for its
energy. Therefore, it is not surprising that compensatory
mechanisms are in place to avoid deficiency or dysmetabolism
of essential metals, preventing adverse effects on CNS
functions. Indeed, compensatory mechanisms maintain
physiological levels of essential elements, in response to the
altered iron and copper levels in PrPC-null mouse serum.
This is exemplified by the modulation of TfR1,Tf, Ctr1, and
Atp7a.
These results indicate that the absence of PrPC leads to
alterations in copper and iron functional values, with iron
metabolism affected by low Cp activity. Interestingly, our data
are in agreement with previously published works, showing
a reduction in cerebrospinal fluid ferroxidase activity from
Alzheimer’s and Parkinson’s disease patients (Boll et al., 1999,
2008; Capo et al., 2008; Olivieri et al., 2011). Similarly to
our observations, they identified the impairment of copper
incorporation in Cp as the main cause of ferroxidase activity
reduction. The relevance of PrPC loss-of-function on the
modulation of copper metabolism has been confirmed in prion
disorders. Indeed, the alteration of copper coordination by PrPC
is a key factor in prion pathologies, and can determine the disease
onset (Stevens et al., 2009). Moreover, prion-infected brains show
impairments in iron metabolism that resemble those observed in
PrPC knockout mice (Singh et al., 2009a). Our findings increase
the understanding of PrPC role in copper and iron metabolism,
and provide a link with pathogenic mechanism involved in prion
diseases.
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